ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Recommendation of “Buy” by Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been assigned an average rating of “Buy” from the five brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $169.00.

ICUI has been the subject of a number of analyst reports. Piper Sandler lowered their target price on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Weiss Ratings upgraded shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, KeyCorp reduced their price target on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a report on Monday, April 27th.

Insider Buying and Selling

In other news, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares of the company’s stock, valued at $978,363.60. The trade was a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC purchased a new position in ICU Medical during the fourth quarter worth about $32,000. Covestor Ltd boosted its holdings in ICU Medical by 70.7% during the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 236 shares during the last quarter. Strs Ohio boosted its holdings in ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares during the last quarter. Rockefeller Capital Management L.P. boosted its holdings in ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in ICU Medical during the fourth quarter worth about $120,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Price Performance

ICUI stock opened at $122.99 on Friday. The company has a fifty day moving average price of $126.39 and a 200-day moving average price of $138.44. The company has a market capitalization of $3.07 billion, a P/E ratio of 66.48, a PEG ratio of 1.76 and a beta of 0.74. ICU Medical has a 52-week low of $107.00 and a 52-week high of $160.29. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.78 by $0.19. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The firm had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. During the same quarter last year, the firm earned $1.72 earnings per share. The company’s revenue for the quarter was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities analysts expect that ICU Medical will post 6.31 EPS for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.